All In Biotech

Drug Trial Radar · NCT03596762

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause

Last checked: Nov 19, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Nov 20, 2018

Primary completion

Nov 21, 2019

Study completion Nov 21, 2019

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Nerre Therapeutics Ltd.
First posted
Jul 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Conditions

  • Menopause
  • Hot Flashes
  • Night Waking

Interventions

  • Elinzanetant (BAY3427080)Drug

    BAY3427080 capsules

  • PlaceboDrug

    Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4Time frame: From baseline to Week 4
  2. Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12Time frame: From baseline to Week 12
  3. Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4Time frame: From baseline to Week 4
  4. Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12Time frame: From baseline to Week 12

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Study Site 12

    Mesa, Arizona

  • Study Site 19

    San Diego, California

  • Study Site 13

    Aventura, Florida

  • Study Site 15

    Lake Worth, Florida

  • Study Site 18

    Atlanta, Georgia

  • Study Site 16

    New Orleans, Louisiana

  • Study Site 10

    Boston, Massachusetts

  • Study Site 11

    Boston, Massachusetts

  • Study Site 17

    Las Vegas, Nevada

  • Study Site 14

    Houston, Texas

  • Study Site 50

    Red Deer, Alberta, Canada

  • Study Site 51

    Mission, British Columbia, Canada

  • Study Site 54

    Guelph, Ontario, Canada

  • Study Site 52

    Scarborough Village, Ontario, Canada

  • Study Site 53

    Toronto, Ontario, Canada

  • Study Site 37

    Blackpool, United Kingdom

  • Study Site 34

    Cannock, United Kingdom

  • Study Site 31

    Glasgow, United Kingdom

  • Study Site 39

    Leeds, United Kingdom

  • Study Site 38

    Liverpool, United Kingdom

  • Study Site 30

    London, United Kingdom

  • Study Site 36

    Manchester, United Kingdom

  • Study Site 33

    Poole, United Kingdom

  • Study Site 32

    Southport, United Kingdom

  • Study Site 35

    Stockton-on-Tees, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.